Kevzara FDA Approval: Pharmacology and Rheumatoid Arthritis
This paper examines Kevzara (sarilumab), approved by the U.S. Food and Drug Administration on May 22, 2017, for the treatment of moderate to severe active rheumatoid arthritis in adults. The paper describes Kevzara's pharmacodynamic and pharmacokinetic properties as an interleukin-6 (IL-6) receptor antagonist, provides an overview of the rheumatoid arthritis disease state, and compares Kevzara to conventional therapies such as corticosteroids and nonsteroidal anti-inflammatory drugs. Potential risks and monitoring parameters are identified, including the screening for latent tuberculosis and vigilance for opportunistic infections. The paper concludes with a clinical recommendation that acknowledges the drug's promise while noting limitations in racial diversity among trial subjects.
- Introduction: FDA approval context and paper scope
- Kevzara: Description, Pharmacodynamics, and Pharmacokinetics: IL-6 antagonist mechanism and administration details
- Overview of the Rheumatoid Arthritis Disease State: RA symptoms, prevalence, and aging demographics
- How Kevzara Differs from Currently Available Therapies: Subcutaneous dosing vs. daily oral treatments
- Potential Risks and Monitoring Parameters: Infections, blood counts, and required monitoring
- Clinical Recommendation: Kevzara or Existing Alternatives?: Prescribing rationale and racial diversity caveat
- Conclusion: Summary of findings and clinical takeaways
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Follows a clear, logical structure that moves from drug description to disease context, comparative analysis, risk assessment, and clinical recommendation — mirroring real-world prescribing decision frameworks.
- Integrates FDA prescribing information alongside peer-reviewed sources, demonstrating appropriate use of both regulatory and academic evidence.
- Concludes the clinical recommendation section with a meaningful caveat about racial diversity in drug trials, showing critical thinking beyond surface-level approval endorsement.
Key academic technique demonstrated
The paper effectively uses direct quotation from a peer-reviewed source to anchor a pharmacological claim (the efficacy of IL-6 receptor antagonists), then supports it with FDA documentation. This layering of evidence — combining clinical trial snapshots, prescribing information, and journal articles — is a strong model for pharmacy and health sciences writing.
Structure breakdown
The paper is organized into seven sections: an introduction establishing clinical context and scope; a pharmacology section covering mechanism of action and administration; a disease-state overview with epidemiological data; a comparative section contrasting Kevzara with conventional treatments; a detailed risk and monitoring section using a bulleted list for clarity; a short but substantive prescribing recommendation with a racial equity caveat; and a summary conclusion tying all threads together.
Introduction
The exhaustive and lengthy approval process used by the U.S. Food and Drug Administration (FDA) means that when new drugs are released, they are considered sufficiently safe for human use as directed by physicians. This approval process, however, also means that relatively few new drugs are approved each year, including Kevzara, which is used to treat adult rheumatoid arthritis and was approved for release on May 22, 2017 (Novel drug approvals, 2017). Given the rapid increase in the elderly demographic in the U.S. in recent years — a trend projected to continue well into the 21st century (Poterba, 2016) — novel treatments for adult rheumatoid arthritis represent important and timely advances in drug therapy.
This paper provides a description of Kevzara, including its pharmacodynamic and pharmacokinetic properties, as well as an overview of the rheumatoid arthritis disease state for which it is used. In addition, a description of what distinguishes this drug from other currently available therapies is followed by a discussion of the potential risks associated with this agent and any monitoring parameters that are necessary. Finally, an analysis of whether this author would personally prescribe Kevzara or rely on currently available alternatives is followed by a summary of the research and important findings in the conclusion.
Kevzara: Description, Pharmacodynamics, and Pharmacokinetics
The newly approved Kevzara was developed for the treatment of adults who suffer from moderate to severe active rheumatoid arthritis following the prescription of at least one other disease-modifying anti-rheumatic drug (DMARD) that was either not tolerated or failed to produce the desired clinical results (Drug trials snapshot, 2017). This drug comprises an interleukin-6 (IL-6) receptor antagonist (Highlights of prescribing information, 2017). A growing body of research indicates that IL-6 receptor antagonism in particular represents an efficacious intervention for rheumatoid arthritis that cannot be well managed by other means (Hennigan & Kavanaugh, 2008). In this regard, Hennigan and Kavanaugh (2008) report that "efficacy achieved with certain agents [such as] IL-6, a cytokine with effects on numerous cell types, including those involved in the pathogenesis of rheumatoid arthritis" (p. 767).
Overview of the Rheumatoid Arthritis Disease State
Rheumatoid arthritis is an inflammatory autoimmune disease that causes stiffness, swelling, and pain in the human joints — typically more than one — and if one limb develops the disease, it is probable that the other will as well (Overview of rheumatoid arthritis, 2017). The disease also fatigues sufferers, who may also develop fevers; its effects tend to vary in intensity over time in some individuals, while others experience a more severe form that can persist for a number of years or even for an entire lifetime (Overview of rheumatoid arthritis, 2017). In fact, the more severe forms of rheumatoid arthritis can result in significant damage to the affected joints (Overview of rheumatoid arthritis, 2017).
Although the incidence of rheumatoid arthritis — that is, the number of new cases identified each year — has been declining in recent years, there has been a corresponding trend toward onset of the disease at older ages as well (Harris, 2009). At present, the prevalence of rheumatoid arthritis, meaning the number of people currently living with the disease, is approximately 0.6% of the U.S. population, or about 1.29 million citizens (Rheumatoid arthritis statistics, 2017).
Conclusion
The research showed that only a few dozen new drugs are approved by the U.S. Food and Drug Administration each year, and that one of the most recently approved was Kevzara, developed for the treatment of rheumatoid arthritis when other drugs failed to produce the desired clinical outcomes or were not well tolerated by patients. The research also showed that although the incidence of rheumatoid arthritis has been declining in recent years, the rapidly aging U.S. population will likely reverse this trend unless additional efficacious treatments such as Kevzara are developed and approved by the FDA. Finally, because the drug trials conducted to date have largely been limited to white subjects, clinicians should ensure that patients from minority populations are carefully assessed and closely monitored throughout the duration of Kevzara's use.
References
Drug trials snapshot. (2017). U.S. Food & Drug Administration. Retrieved from
Harris, E. D. (2009, September). The changing dimensions of rheumatoid arthritis and its treatment. Bulletin of the World Health Organization, 81(9), 631.
Hennigan, S. & Kavanaugh, A. (2008, August). Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management, 4(4), 767–775.
Highlights of prescribing information. (2017). U.S. Food & Drug Administration. Retrieved from
Novel drug approvals. (2017). U.S. Food & Drug Administration. Retrieved from
Overview of rheumatoid arthritis. (2017). National Institute of Arthritis and Musculoskeletal and Skin Diseases. Retrieved from
Poterba, J. (2016, January). Economic implications of demographic change. Business Economics, 51(1), 3–5.
Rheumatoid arthritis in depth. (2017). National Center for Complementary and Integrative Health. Retrieved from
Rheumatoid arthritis statistics. (2017). Health Union. Retrieved from https://rheumatoidarthritis.net/what-is-ra/ra-statistics/.
Always verify citation format against your institution’s current style guide requirements.